ScreenerHero

TARAProtara Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · protaratx.com
3.850USD-2.78%Mkt Cap: 227.52M $P/E: —

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigatio…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap227.52M $
Enterprise Value90.73M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-57.44M $
Revenue/Share—
Last Price3.850 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees46
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS74365U1079
Valuation
P/E (Trailing)—
P/E (Forward)-2.31
PEG—
EV/EBITDA-1.19
EV/Revenue—
P/S—
P/B1.19
EPS (TTM)-1.34
EPS (Forward)-1.69
52W Range
2.97018% of range7.820
52W High7.820 USD
52W Low2.970 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-29.24%
ROA-27.42%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-56.37M $
CapEx (TTM)94.00K $
FCF Margin—
FCF Yield-17.80%
Net Debt-139.75M $
Net Debt/EBITDA1.83
Balance Sheet
Debt/Equity0.02
Current Ratio10.97
Quick Ratio10.79
Book Value/Sh3.291 USD
Cash/Share2.411 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 10, 2020
Splits
Last Split1:40
Split DateJan 10, 2020
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)25.71 USD
Upside (mean)+567.9%
Target Range20.00 USD – 30.00 USD
$20.00+567.9% to mean$30.00
# Analysts7
Ownership
Shares Out.59.10M
Float54.88M
Insiders2.30%
Institutions78.36%
Short Interest
Short Ratio7.5d
Short % Float8.14%
Short % Out.8.00%
Shares Short4.50M
Short (prev mo.)4.34M
Technical
SMA 504.018 (-4.2%)
SMA 2005.191 (-25.8%)
Beta1.49
S&P 52W Chg18.16%
Avg Vol (30d)402.12K
Avg Vol (10d)367.48K
Technical Indicators
RSI (14)40.7
MACD-0.0471
MACD Signal-0.0435
MACD Hist.-0.0036
BB Upper4.146 USD
BB Middle3.981 USD
BB Lower3.815 USD
BB Width8.30%
ATR (14)0.1716 USD
Vol Ratio (20d)0.61x